New epilepsy drug vormatrigine tested for Long-Term safety in 700 adults

NCT ID NCT07287163

ENROLLING_BY_INVITATION Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study is testing the long-term safety of a once-daily drug called vormatrigine in 700 adults with focal or generalized tonic-clonic seizures. Participants must have already taken vormatrigine in a previous trial or program. The main goal is to check for side effects and changes in vital signs, not to measure how well the drug stops seizures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vormatrigine (a once-daily oral drug for seizures)
What this could lead to: If successful, this could confirm that vormatrigine is safe for long-term use and help control seizures in adults with epilepsy.
What could go wrong: This is an extension study focused on safety, not on proving the drug works. It only includes people who already tolerated the drug, so results may not apply to all patients. Side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy epilepsy with generalized tonic-clonic seizures focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY, TONIC-CLONIC FOCAL SEIZURE PRIMARY GENERALIZED SEIZURE

Contacts and locations

Locations

Praxis Research Site

Miami, Florida, 33186, United States
Praxis Research Site

Miami Lakes, Florida, 33016, United States
Praxis Research Site

Naples, Florida, 34116, United States
Praxis Research Site

Lafayette, Louisiana, 70508, United States
Praxis Research Site

Bethesda, Maryland, 20817, United States
Praxis Research Site

Plymouth, Michigan, 48170, United States
Praxis Research Site

Chesterfield, Missouri, 63005, United States
Praxis Research Site

Hackensack, New Jersey, 07601, United States
Praxis Research Site

Amherst, New York, 14226, United States
Praxis Research Site

Middletown, New York, 10941, United States
Praxis Research Site

New York, New York, 10016, United States
Praxis Research Site

Niagara Falls, New York, 14304, United States
Praxis Research Site

Philadelphia, Pennsylvania, 19107, United States
Praxis Research Site

El Paso, Texas, 79912, United States
Praxis Research Site

Houston, Texas, 77058, United States
Praxis Research Site

Porto Alegre, Rio Grande do Sul, Brazil
Praxis Research Site

São José do Rio Preto, São Paulo, Brazil
Praxis Research Site

Bielefeld, 33617, Germany
Praxis Research Site

Tübingen, 72076, Germany
Praxis Research Site

Pozzilli, Isernia, Italy
Praxis Research Site

Bosisio Parini, Lecco, Italy
Praxis Research Site

Milan, 20133, Italy
Praxis Research Site

Naples, Italy
Praxis Research Site

Pavia, 27100, Italy
Praxis Research Site

Pisa, Italy
Praxis Research Site

Ponderano, Italy
Praxis Research Site

Roma, Italy
Praxis Research Site

Bydgoszcz, 85163, Poland
Praxis Research Site

Katowice, 40123, Poland
Praxis Research Site

Lublin, Poland
Praxis Research Site

Warsaw, Poland
Praxis Research Site

Barcelona, 08003, Spain
Praxis Research Site

Madrid, 28040, Spain
Praxis Research Site

Málaga, 29010, Spain
Praxis Research Site

Terrassa, 08222, Spain
Praxis Research Site

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.